Monday November 23 2009 | Biotechnology feed | All feeds
|
|
Scancell Limited
Download detailed PDF Members: Scancell Ltd is a company focused on the discovery and development of products that harness the immune system in a unique way to treat or prevent cancer. Founded in 1997 as a spin-out from the University of Nottingham, Scancell is based in state-of-the-art facilities at the BioCity innovation and technology centre, Nottingham. The Company, which currently employs 12 staff, has secured £4.7million of private equity and commercial funding to date. Scancell is focused in two areas: therapeutic monoclonal antibodies and cancer vaccines. Scancell’s first antibody, an EGFr antibody licensed to ISU Abxis, is expected to enter clinical trials within 12 months. Scancell has two further direct killing therapeutic antibodies against proprietary targets in preclinical development – both products are expected to be in clinical testing by the end of 2006. In addition, Scancell has two further vaccine products in development based on its proprietary ImmunoBody® vaccine technology.
This page has been viewed 429 times since April 2007, the link to the organisation's website has been followed 94 times Recent Search Terms used to find this page: SCANCELL LTD | scancell ltd | scancell nottingham | scancell nottingham | scancell ltd notts | Scancell Limited | scancell | lindy durrant 2009 | . Search for more companies in Nottingham Search for more companies in Nottinghamshire This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for Scancell Limited | ||||||||||||||||||||||||||||||||||||||||||||||
|